QIAGEN powered by

Monday, June 24, 2019

QIAGEN Clinical Insight surpasses 1 million patient test cases analyzed and interpreted



We are proud to announce that QIAGEN Clinical Insight (QCI®), QIAGEN’s clinical decision support platform has achieved a milestone: over 1 million patient test cases analyzed and interpreted.

Supporting more than 1,000 clinical laboratories and physicians worldwide, the cloud-based QCI platform provides all of the capabilities required to transform complex data from next-generation sequencing (NGS) into actionable insights. The two platform components—QCI Analyze and QCI Interpret—simplify and streamline variant analysis and interpretation, yielding standardized, evidence-based reports with actionable information.

“Surpassing 1 million patient test cases is strong validation for QCI. Over 1,000 customers worldwide have processed patient tests, ranging from targeted panels to whole exome or genome results across multiple indications, germline to somatic cancer, to gain actionable insights from the QIAGEN Knowledge Base.”

Dr. Jonathan Sheldon, Senior Vice President, QIAGEN Bioinformatics


When a genetic testing lab runs NGS data through QCI, the software computes variant classifications according to guidelines set by industry experts, such as ACMG, AMP, ASCO, and CAP. QCI bases variant classifications on the evidence obtained from multiple sources, including full-text articles and public and private databases, all of which are contained within the QIAGEN Knowledge Base.

“This knowledge base is the industry’s most expansive collection of expert-curated biological and clinical findings built from over 20 years of manual data and literature curation, enabling deep clinical insights across a broad range of disease indications,” says Sheldon. “While handling 1 million patient cases is a monumental milestone, this is just the beginning. We are now supporting large-scale programs for precision medicine like Genomics England and the National Cancer Center Japan and are seeing the realization of our goal of using bioinformatics to make improvements in life possible.”


How QCI is used throughout the world

The cloud-based QCI software delivers insights to clinical laboratories and physicians in North America, Europe and the Asia-Pacific region, enabling and advancing the practice of precision medicine.

  • Japan’s National Cancer Center (NCC) uses QCI as part of Japan’s Ministry of Health, Labour and Welfare’s precision medicine program, for the analysis, interpretation and reporting of molecular oncology and oncogenetic screening of cancer patients to contribute to the identification of targeted therapy treatment and clinical trial options.

Read press release

  • Investigators in the UK are using QCI to identify clinically actionable mutations from blood-based sequencing results. Recently, Nature Medicine published the first results from the UK’s TARGET (Tumor chARacterisation to Guide Experimental Targeted therapy) study, showing that a small volume of blood can contain up-to-date genetic information about a patient’s cancer to inform treatment choices. In this feasibility study of the first 100 patients, 11 were molecularly matched and enrolled into an available therapy using QCI.

Read article

  • Dr. Andreas Rump of the Institute for Clinical Genetics at Technical University Dresden uses QCI for rapid and comprehensive NGS variant interpretation. Attend our webinar, July 11 at 1 PM ET, as Dr. Rump shares his lab’s experience scaling and standardizing NGS variant intepretation and reporting for inherited and rare diseases using QCI.

Register for webinar


To learn more about QCI and how the platform is advancing precision medicine, visit our clinical solutions web page.